Page last updated: 2024-10-23

bisoprolol and Hypotension, Orthostatic

bisoprolol has been researched along with Hypotension, Orthostatic in 3 studies

Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.

Hypotension, Orthostatic: A significant drop in BLOOD PRESSURE after assuming a standing position. Orthostatic hypotension is a finding, and defined as a 20-mm Hg decrease in systolic pressure or a 10-mm Hg decrease in diastolic pressure 3 minutes after the person has risen from supine to standing. Symptoms generally include DIZZINESS, blurred vision, and SYNCOPE.

Research Excerpts

Excerpt	Relevance	Reference
"However, orthostatic hypotension (OH) is sometimes caused by BBs."	5.56	Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T; Sano, T, 2020)
"However, orthostatic hypotension (OH) is sometimes caused by BBs."	1.56	Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T; Sano, T, 2020)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Piani, F	1
Landolfo, M	1
Fiorini, G	1
D'Addato, S	1
Mancia, G	1
Borghi, C	1
Kiuchi, S	1
Hisatake, S	1
Kabuki, T	1
Oka, T	1
Dobashi, S	1
Fujii, T	1
Sano, T	1
Ikeda, T	1
Freitas, J	1
Santos, R	1
Azevedo, E	1
Costa, O	1
Carvalho, M	1
de Freitas, AF	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist[NCT03070730]			Phase 1/Phase 2	8 participants (Actual)	Interventional	2011-08-15	Terminated (stopped due to Recruitment was slow and subjects declined participation after signing the ICF.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Trials

1 trial available for bisoprolol and Hypotension, Orthostatic

Article	Year
Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2000, Volume: 10, Issue:5 Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Bisoprolol; Blood Pressure; Cardiac Output; Electroc	2000

Other Studies

2 other studies available for bisoprolol and Hypotension, Orthostatic

Article	Year
Severe impaired blood pressure control caused by baroreflex failure as a late sequela of neck irradiation. Journal of hypertension, 2020, Volume: 38, Issue:3 Topics: Antihypertensive Agents; Baroreflex; Bisoprolol; Blood Pressure; Humans; Hypertension; Hypotension,	2020
Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension. Clinical and experimental hypertension (New York, N.Y. : 1993), 2020, Aug-17, Volume: 42, Issue:6 Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Pressure; Female; Heart Failure; Humans; Hypert	2020